Extavia® (interferon beta-1b)

Parent company: Novartis Pharmaceuticals Corp.

• Administered by subcutaneous injection every other day; dose is 250 mcg.
  
  
• Approved for relapsing forms of MS and for individuals with CIS.
  
  
• Extavia is an interferon beta-1b that is biologically identical to Betaseron and made in an identical process, but marketed by a different company. It was released in early 2010.
  
  
• Extavia shares all prescribing, side effect, and safety information with Betaseron. The two pharmaceutical companies manage the patient support programs differently; prices and copayments may also vary. The latest information is available through the patient-support programs at these two companies. For more information, visit www.mymsaa.org, and select "About MS," and "Sources of Information."